Propranolol vs Carvedilol
## Overview
Propranolol and carvedilol are both non-selective beta-blockers, but carvedilol adds alpha-1 receptor blockade and antioxidant activity. Propranolol has the broadest indication spectrum of any beta-blocker; carvedilol is optimized for cardiovascular indications particularly HFrEF.
## Mechanism of Action
Propranolol: non-selective beta-1 + beta-2 blockade, membrane stabilizing activity (Class I antiarrhythmic). Carvedilol: beta-1 + beta-2 + alpha-1 blockade, antioxidant properties, no membrane stabilizing activity.
## Pharmacokinetics
Both are lipophilic and hepatically metabolized. Propranolol has very high first-pass effect (bioavailability ~25–30%); carvedilol bioavailability ~25–35%. Carvedilol is a racemate; the S(-) form produces beta-blockade, both enantiomers produce alpha-1 blockade.
## Pharmacodynamics and Indications
Carvedilol is preferred for HFrEF (multiple pivotal trials). Propranolol is used for essential tremor, migraine prophylaxis, thyrotoxicosis, portal hypertension, and pheochromocytoma. Carvedilol lacks these non-cardiac indications.
## Key Takeaways
- Both non-selective; carvedilol adds alpha-1 vasodilation
- Propranolol: wider non-cardiac indications (tremor, thyrotoxicosis, migraine)
- Carvedilol: superior for HFrEF management
الخلاصة
Carvedilol is preferred for heart failure and post-MI LV dysfunction. Propranolol is selected when non-cardiac indications (tremor, hyperthyroidism, migraine, portal hypertension) require beta-blockade without the alpha-1 component.